Skip to content

Company · founded 2018

Cerevel Therapeutics (United States)

Cambridge, United States · cerevel.com

Manage this page

Citations, last 5 years: 756
Works, last 5 years: 83
h-index: 34
Scientists listed: 4
Grants since 2016: 3

Grants received

2021–2025 · cooperative agreement · UH3

CVL-354, a kappa opioid receptor antagonist for treatment of opioid use disorder, withdrawal and relapse

Georgette Suidan · Cerevel Therapeutics (United States) · funded by National Institutes of Health

$2.7MNeuropeptides and Animal Physiology

2021–2023 · cooperative agreement · UG3

CVL-354, a kappa opioid receptor antagonist for treatment of opioid use disorder, withdrawal and relapse

Philip Iredale · Cerevel Therapeutics (United States) · funded by National Institutes of Health

$5.4MNeuropeptides and Animal Physiology

2021–2026 · cooperative agreement · UH3

CVL-354, a kappa opioid receptor antagonist for treatment of opioid use disorder, withdrawal and relapse

Philip Iredale · Cerevel Therapeutics (United States) · funded by National Institutes of Health

$2.7MNeuropeptides and Animal Physiology